PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022 10:30 ET
|
PMV Pharmaceuticals, Inc.
Oral presentation at ASCO to highlight initial data from ongoing Phase 1 study of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have...
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
March 01, 2022 07:15 ET
|
PMV Pharmaceuticals, Inc.
Continued progress with Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutationStrong cash, cash...
PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference
February 28, 2022 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day
February 03, 2022 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharma Announces Changes to its Board of Directors
January 06, 2022 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference
November 22, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
November 12, 2021 07:15 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a clinical-stage oncology company pioneering the discovery and development of small molecule therapies...
PMV Pharmaceuticals Appoints Tim Smith as Senior Vice President, Head of Corporate Development
September 09, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
September 02, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
August 13, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
Continued enrollment in Phase 1/2 trial of first-in-class p53 Y220C reactivator PC14586 CRANBURY, N.J., Aug. 13, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a...